Marinus Pharmaceuticals, Inc
MRNS
MRNS was delisted on the 10th of February, 2025.
38 hedge funds and large institutions have $118M invested in Marinus Pharmaceuticals, Inc in 2017 Q3 according to their latest regulatory filings, with 23 funds opening new positions, 9 increasing their positions, 2 reducing their positions, and 9 closing their positions.
1,050% more capital invested
Capital invested by funds: $10.3M → $118M (+$108M)
350% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 2
156% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 9
58% more funds holding
Funds holding: 24 → 38 (+14)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
+$10.2M |
| 2 |
GPCM
Granite Point Capital Management
Boston,
Massachusetts
|
+$5.38M |
| 3 |
PA
Perceptive Advisors
New York
|
+$4.07M |
| 4 |
DM
Deerfield Management
New York
|
+$3.8M |
| 5 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$3.28M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$1.82M |
| 2 |
JGC
J. Goldman & Co
New York
|
-$940K |
| 3 |
ARTA
A.R.T. Advisors
New York
|
-$66K |
| 4 |
BFM
Boothbay Fund Management
New York
|
-$43K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$14.6K |
MRNS Hedge Fund Activity: Q3 2017 in Review
38 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Marinus Pharmaceuticals, Inc (MRNS) for Q3 2017, worth a combined $118M — up 1,050% from $10.3M a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new MRNS positions and 9 closed out — a net gain of 14 holders — while 9 added to existing stakes and 2 trimmed.
The largest buyer was EcoR1 Capital, opening a new position worth an estimated $10.2M. The largest seller was Sphera Funds Management, exiting entirely with an estimated $1.82M sold.
- 38 institutional investors held Marinus Pharmaceuticals, Inc (MRNS) as of Q3 2017, up from 24 in Q2 2017.
- Funds reported $118M of Marinus Pharmaceuticals, Inc stock for Q3 2017, up 1,050% quarter-over-quarter.
- 23 funds opened new Marinus Pharmaceuticals, Inc positions in Q3 2017 and 9 closed out, a net change of +14 holders.
- The largest Marinus Pharmaceuticals, Inc buyer in Q3 2017 was EcoR1 Capital, an estimated $10.2M added.
- The largest Marinus Pharmaceuticals, Inc seller in Q3 2017 was Sphera Funds Management, an estimated $1.82M sold.
Based on aggregated 13F filings for Q3 2017.